Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Nitisinone Coverage Policy Update | OpenPay…
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C13398-A

    Nitisinone Coverage for Hereditary Tyrosinemia Type 1 and Alkaptonuria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C13398-A alerts

    Get alerted when Policy C13398-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for oral nitisinone products used for hereditary tyrosinemia type 1 and, for Harliku only, alkaptonuria. It applies to Molina members subject to benefit eligibility, formulary requirements, and documented clinical and monitoring criteria.

    Policy Summary
    PayerMolina Healthcare
    PolicyNitisinone Coverage for Hereditary Tyrosinemia Type 1 and Alkaptonuria
    Policy CodePolicy C13398-A
    Change TypeModified
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming the diagnosis, required baseline testing, medical necessity, and applicable monitoring results.
    SourceLink
    POLICY UPDATE CHANGES

    The Q3 2026 revision updated the products affected, diagnosis requirements, required medical information, continuation criteria, duration of approval, age restrictions, quantity, FDA-approved uses, background, and references.

    12 monthsAuthorization duration
    85%Continuation adherence threshold
    1 mg/kg twice dailyMaximum HT-1 dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NoneAge restriction for Nityr and Orfadin
    OralRoute of administration

    Coverage Criteria

    Initial therapy: hereditary tyrosinemia type 1

    Covered for initial therapy when all criteria are met.

    Initial HT-1 therapy

    • HT-1 diagnosis and treatment readiness

      • Diagnosis of hereditary tyrosinemia type 1 (HT-1) is documented.
      • HT-1 confirmation

        • Diagnosis is confirmed by detection of elevated succinyl acetone in blood or urine.
        • DNA testing confirms a mutation in the fumarylacetoacetate hydrolase (FAH) gene.
      • Baseline succinyl acetone level is documented.
      • The prescriber attests that the member has been counseled regarding dietary restriction of tyrosine and phenylalanine.
      • There is no evidence of intolerable adverse effects or drug toxicity.
      • Baseline ophthalmologic testing, hepatic imaging, and baseline laboratory evaluation have been obtained and reviewed, including liver evaluation, renal function, plasma amino acids, CBC, and serum alpha-fetoprotein (AFP).
      • If the requested product is non-formulary or non-preferred, documentation shows trial and failure of, or serious side effects to, a majority (not more than three) of the preferred formulary or PDL alternatives for the diagnosis, including medications tried, trial dates, and reasons for treatment failure.

        This requirement applies only when the requested product is non-formulary or non-preferred.

    Initial therapy: alkaptonuria

    Covered for initial therapy when all criteria are met.

    Initial alkaptonuria therapy

    • Diagnosis of alkaptonuria is documented.
    • Diagnosis is confirmed by urinary homogentisic acid (HGA) and a genetic defect of the HGD gene.
    • Baseline urinary homogentisic acid (HGA) level is documented.

    Continuation therapy: hereditary tyrosinemia type 1

    Covered for continuation when all criteria are met.

    Continuation HT-1 therapy

    • Monitoring has occurred for plasma amino acids, liver function, serum AFP increases, CBC, and ophthalmologic side effects testing.

      Patients with increasing AFP concentrations or signs of liver nodules should be evaluated for hepatic malignancy.

    • Adherence

      • Adherence to therapy is at least 85% of the time as verified by the prescriber or member medication fill history.≥ 85%
      • Adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.< 85%

    Continuation therapy: alkaptonuria

    Covered for continuation when all criteria are met.

    Continuation alkaptonuria therapy

    • Adherence

      • Adherence to therapy is at least 85% of the time as verified by the prescriber or member medication fill history.≥ 85%
      • Adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.< 85%
    • There is no evidence of intolerable adverse effects or drug toxicity, including elevated tyrosine levels, corneal ulcers, corneal opacities, keratitis, conjunctivitis, ocular pain, or photophobia.

    Uses of nitisinone other than the covered indications of hereditary tyrosinemia type 1 and, for Harliku, alkaptonuria—including Harliku, Orfadin, or Nityr used outside those indications—are considered experimental or investigational and are subject to Molina’s Off-Label policy. Coverage is not established by this policy for those uses.

    Coding and Dosing Parameters

    HCPCSHCPCS
    NADESCRIPTION
    HT-1 Maximum Dose
    Maximum oral dose1 mg/kg orally twice daily
    Daily equivalent2 mg/kg/day
    RouteOral
    Continuation Adherence
    Required adherenceAt least 85% of the time
    VerificationPrescriber verification or member medication fill history
    Temporary-discontinuation exceptionAdherence below 85% is permitted when surgery or treatment of an infection causes temporary discontinuation

    Provider Requirements and Authorization

    Prior Authorization

    Initial HT-1 Authorization Required

    Submit an authorization request for nitisinone (Nityr or Orfadin) for documented hereditary tyrosinemia type 1 (HT-1), including the required diagnostic, baseline, safety, and prescriber attestations. Coverage applies when used with dietary restriction of tyrosine and phenylalanine.

    • Documented HT-1 diagnosis and required confirmatory testing.
    • Baseline succinyl acetone level and required baseline evaluations.
    • Prescriber attestation regarding dietary counseling and absence of intolerable toxicity.
    Prior Authorization

    HT-1 Reauthorization Documentation

    For reauthorization of HT-1 treatment, submit evidence of ongoing monitoring, adherence, clinical safety, and biochemical response to nitisinone.

    • Monitoring of plasma amino acids, liver function, serum AFP, CBC, and ophthalmologic side effects.
    • Adherence of at least 85%, unless a temporary interruption was required for surgery or infection.

    Clinical Background

    Hereditary tyrosinemia type 1 (HT-1) is a rare, severe disorder of tyrosine metabolism caused by fumarylacetoacetate hydrolase deficiency. Toxic metabolites, including fumarylacetoacetate and succinyl acetone, accumulate and can damage the liver and kidneys. Nitisinone is the primary treatment for HT-1 because it limits formation of these toxic compounds and is used with dietary restriction of tyrosine and phenylalanine.

    Alkaptonuria is a rare autosomal recessive disorder caused by deficient homogentisic acid dioxygenase activity. The resulting elevation of homogentisic acid can cause ochronosis, osteoarthritis, pain, reduced joint mobility, and possible cardiac and renal complications. Under this policy, nitisinone use for alkaptonuria is limited to Harliku.

    Key Definitions

    Hereditary Tyrosinemia Type 1 (HT-1)
    DefinitionA rare inherited metabolic disorder caused by fumarylacetoacetate hydrolase deficiency
    Metabolic effectTyrosine and toxic metabolites, including fumarylacetoacetate and succinyl acetone, accumulate in the body
    Disease characteristicsMay cause liver failure, hepatocellular carcinoma, kidney dysfunction, skeletal changes, and neurologic manifestations
    Alkaptonuria (AKU)
    DefinitionA rare autosomal recessive genetic disorder caused by deficient homogentisic acid dioxygenase activity
    Metabolic effectThe deficiency results in elevated homogentisic acid, which polymerizes and forms pigment deposits in connective tissue

    Initial Therapy

    Initial HT-1 therapy

    Initial HT-1 therapy requires all applicable criteria.

    • Diagnosis of hereditary tyrosinemia type 1 (HT-1) is documented.
    • HT-1 confirmation

      • Diagnosis is confirmed by detection of elevated succinyl acetone in blood or urine.
      • DNA testing confirms a mutation in the fumarylacetoacetate hydrolase (FAH) gene.
    • Baseline succinyl acetone level is documented.
    • The prescriber attests that the member has been counseled regarding dietary restriction of tyrosine and phenylalanine.

    Continuation Therapy

    HT-1 continuation

    HT-1 continuation requires all listed criteria.

    • Monitoring has occurred for plasma amino acids, liver function, serum AFP increases, CBC, and ophthalmologic side effects testing.

      Patients with increasing AFP concentrations or signs of liver nodules should be evaluated for hepatic malignancy.

    • Adherence

      • Adherence to therapy is at least 85% of the time as verified by the prescriber or member medication fill history.≥ 85%
      • Adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.< 85%

    Preferred Product Requirements

    StepRequirementDocumentation required
    1Generic drugs must be dispensed when available. For a non-formulary or non-preferred product, trial and failure of, or serious side effects to, a majority (not more than 3) of the preferred formulary or PDL alternatives for the diagnosis are required.Submit the medication names, trial dates, and reasons for treatment failure or serious side effects.

    Quantity and Dose Limits

    Nityr and Orfadin for HT-1
    ProductsNityr and Orfadin for hereditary tyrosinemia type 1
    Maximum quantity1 mg/kg orally twice daily
    Daily equivalent2 mg/kg/day
    Harliku for Alkaptonuria
    ProductHarliku for alkaptonuria
    Daily quantity limit2 mg daily
    RouteOral

    Site of Care and Administration

    Billing Rule

    Use the pharmacy benefit and self-administration setting

    Oral medications under this policy are recommended for pharmacy benefit coverage and patient self-administration. Prescribe and arrange dispensing consistent with the oral route and pharmacy benefit setting.

    Policy Summary
    PayerMolina Healthcare
    PolicyNitisinone Coverage for Hereditary Tyrosinemia Type 1 and Alkaptonuria
    Policy CodePolicy C13398-A
    Change TypeModified
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit prior authorization documentation confirming the diagnosis, required baseline testing, medical necessity, and applicable monitoring results.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing ParametersProvider Requirements and AuthorizationClinical BackgroundKey DefinitionsInitial TherapyContinuation TherapyPreferred Product RequirementsQuantity and Dose LimitsSite of Care and Administration
    Urinary or blood succinyl acetone levels have decreased from baseline while receiving nitisinone.
    Urinary homogentisic acid levels have decreased from baseline while receiving nitisinone.
  1. Urinary or blood succinyl acetone levels decreased from baseline.
  2. Prior Authorization

    Alkaptonuria Authorization Requirements

    Authorization for Harliku (nitisinone) for alkaptonuria requires documentation of the covered diagnosis and required baseline evidence. Reauthorization requires documentation that treatment remains safe and is producing a biochemical response.

    • Initial requests: confirmed alkaptonuria and baseline urinary homogentisic acid (HGA).
    • Continuation requests: no intolerable adverse effects or drug toxicity and decreased urinary HGA from baseline.
    • Harliku is indicated for adults with alkaptonuria; the policy lists a dosage of 2 mg daily.

    Unsupported block type: prior_auth

    Step Therapy

    Formulary and Preferred-Product Requirements

    Apply Molina’s formulary and preferred-product requirements before requesting a non-formulary or non-preferred product. Generic drugs are mandatory when available, and biosimilars may be preferred when applicable.

    • Use the applicable generic, formulary, or preferred product when available.
    • Requests for a non-preferred product must meet the trial, failure, intolerance, or serious-side-effect requirements described in the policy.
    Documentation Required

    General Medical Necessity Documentation

    Submit complete medical-necessity documentation with the request, including the clinical rationale and records needed to establish eligibility and coverage. Molina may request additional information case by case, particularly when dosing depends on weight, body surface area, or another member-specific measurement.

    • Provide relevant patient records, test results, and credentials of the provider ordering or performing the service.
    • Documentation must support medical necessity, non-investigational status, and that the request falls within the member’s benefit.
    • Coverage remains subject to benefit eligibility and the applicable benefit document.
    Documentation Required

    HT-1 Diagnostic Confirmation

    Document HT-1 with accepted diagnostic confirmation before initiating therapy. The record must establish the hereditary diagnosis and include the required biochemical or genetic evidence.

    • Detection of elevated succinyl acetone (SA) in blood or urine; or
    • DNA testing confirming a mutation in the fumarylacetoacetate hydrolase (FAH) gene.
    • Submit the baseline SA level.
    Documentation Required

    HT-1 Baseline Monitoring

    Before initial HT-1 treatment, the prescriber must attest that baseline ophthalmologic testing, hepatic imaging, and required laboratory evaluations were obtained and reviewed.

    • Liver evaluation, including PT, PTT, and ALT/AST.
    • Renal function, such as BUN and creatinine; plasma amino acids; and CBC.
    • Serum alpha-fetoprotein (AFP) and baseline ophthalmologic evaluation.
    Documentation Required

    Alkaptonuria Diagnostic Confirmation

    For alkaptonuria authorization, document the diagnosis with both biochemical and genetic confirmation and establish a baseline urinary HGA level.

    • Urinary homogentisic acid (HGA) confirming the biochemical abnormality.
    • Genetic defect of the homogentisic acid dioxygenase (HGD) gene.
    • Baseline urinary HGA level.
    Documentation Required

    HT-1 Response Documentation

    Continuation requests for HT-1 must document biochemical response to nitisinone by showing that urinary or blood succinyl acetone has decreased from the pretreatment baseline.

    • Submit the current urinary or blood SA result and the baseline value.
    • The prescriber must verify the response as part of the reauthorization request.
    Documentation Required

    Alkaptonuria Response Documentation

    Continuation requests for alkaptonuria must document that urinary HGA levels have decreased from baseline while the member is receiving nitisinone.

    • Submit the current urinary HGA result and the baseline value.
    • The request must also address ongoing safety and absence of intolerable adverse effects or drug toxicity.

    Unsupported block type: documentation

    Denial Risk

    Noncovered or Investigational Uses

    Uses of nitisinone (Harliku, Orfadin, or Nityr) outside the covered HT-1 and alkaptonuria indications are considered experimental or investigational and are handled under Molina’s Off-Label policy.

    • HT-1 coverage is for nitisinone used with dietary restriction of tyrosine and phenylalanine.
    • Alkaptonuria coverage is for reduction of urinary HGA in adults using Harliku.
    • The policy lists no compendial approved off-label uses.
    Denial Risk

    Insufficient Supporting Documentation

    Molina may deny or delay the request when the submitted records do not adequately support eligibility, medical necessity, the requested indication, or the required clinical documentation.

    • Provide complete patient records, test results, prescriber credentials, and clinical rationale.
    • Insufficient documentation may result in denial of reimbursement or additional review.
    • Molina may take additional action when records indicate inappropriate or excessive billing or other practice concerns.
    Step Therapy

    Non-Preferred Product Requirements

    For a non-formulary or non-preferred product, document a trial and failure of, or serious side effects to, a majority of the preferred formulary or PDL alternatives for the diagnosis.

    • The policy describes a majority of preferred alternatives, not more than three.
    • Include each medication tried, trial dates, and the reason for treatment failure.
    • Document serious side effects or intolerance when that is the basis for the request.
    Disease characteristicsPigment deposition causes ochronosis and may lead to osteoarthritis and cardiac and renal complications
    Succinyl Acetone (SA)
    SpecimenMeasured in blood or urine
    Diagnostic roleElevated succinyl acetone can confirm hereditary tyrosinemia type 1
    Monitoring roleUrinary or blood succinyl acetone levels are monitored for a decrease from baseline during nitisinone treatment
    Homogentisic Acid (HGA)
    SpecimenMeasured in urine
    Diagnostic roleUrinary homogentisic acid is used to confirm alkaptonuria
    Monitoring roleUrinary homogentisic acid levels are monitored for a decrease from baseline during nitisinone treatment
  3. There is no evidence of intolerable adverse effects or drug toxicity.
  4. Baseline ophthalmologic testing, hepatic imaging, and baseline laboratory evaluation have been obtained and reviewed, including liver evaluation, renal function, plasma amino acids, CBC, and serum alpha-fetoprotein (AFP).
  5. If the requested product is non-formulary or non-preferred, documentation shows trial and failure of, or serious side effects to, a majority (not more than three) of the preferred formulary or PDL alternatives for the diagnosis, including medications tried, trial dates, and reasons for treatment failure.

    This requirement applies only when the requested product is non-formulary or non-preferred.

  6. Initial alkaptonuria therapy

    Initial alkaptonuria therapy requires all criteria.

    • Diagnosis of alkaptonuria is documented.
    • Diagnosis is confirmed by urinary homogentisic acid (HGA) and a genetic defect of the HGD gene.
    • Baseline urinary homogentisic acid (HGA) level is documented.
  7. Urinary or blood succinyl acetone levels have decreased from baseline while receiving nitisinone.
  8. Alkaptonuria continuation

    Alkaptonuria continuation requires all listed criteria.

    • Adherence

      • Adherence to therapy is at least 85% of the time as verified by the prescriber or member medication fill history.≥ 85%
      • Adherence is less than 85% because surgery or treatment of an infection caused temporary discontinuation.< 85%
    • There is no evidence of intolerable adverse effects or drug toxicity, including elevated tyrosine levels, corneal ulcers, corneal opacities, keratitis, conjunctivitis, ocular pain, or photophobia.
    • Urinary homogentisic acid levels have decreased from baseline while receiving nitisinone.